Researchers reported in npj Parkinson’s Disease that plasma phosphorylated tau 217 (p-tau217) can detect amyloid-β accumulation in neurodegenerative diseases marked by synuclein pathology. The work, led by Smith, Lorkiewicz, Arslan and colleagues, frames p-tau217 as a potentially sensitive biomarker for tracking amyloid-β changes in synuclein-related conditions. The report emphasizes biomarker utility for diagnosis and monitoring, where synuclein disease populations can complicate staging and treatment-response evaluation. By tying a plasma signal to amyloid-β burden, the study suggests a route for less invasive monitoring of downstream pathology. As therapeutic strategies increasingly depend on biomarker-defined patient selection, plasma-based readouts like p-tau217 could become central to stratifying trial cohorts and interpreting longitudinal response in mixed neurodegenerative syndromes.